Follow us on

Executive Management

The management team of SMS-oncology brings all necessary competences to the oncology drug development arena.

Philine van den Tol
Chief Executive Officer (CEO) / Chief Operating Officer (COO)

Philine van den Tol  

Philine brings nearly 20 years of experience in clinical cancer research to the table. She started her career in 1993 as a physiotherapist working at the Leiden University Medical Center. Her interest in clinical research and oncology led to an employment in 1997, at the Dutch Comprehensive Cancer Center West (CCC) were she was responsible for the project organization, coordination and execution of central and local data management of numerous clinical cancer trials. In 2008 she joined the Dutch Breast Cancer Research Group (BOOG) where she worked as a Clinical Study Manager to initiate, plan and manage clinical scientific breast cancer research. She was a driving force in developing and implementing improvement plans for organization processes, education programs, national quality framework for clinical research and database applications/systems. In addition, she co-founded an independent professional association (NVvOD) in which education and certification of the profession Data Manager was realized. In 2008-2009 Philine successfully studied innovative management at the University of Applied Sciences in Leiden covering main topics of Strategic, Change, Financial and Project management. Philine joined SMS-oncology in January 2012 as Director Operations and became COO a year later. She has successfully led the company and supervised the Clinical Operations group supporting all studies with her substantial experience in managing early and late phase oncology trials. With her strong entrepreneurial sense, can-do attitude and determination for excellence and client satisfaction Philine was promoted to CEO as of January 2016.

Raymond Hoffmans PhD
Chief Business Development Officer (CBDO)

Raymond Hoffmans  

Raymond has over 10 years of experience in cancer research. He received his MSc in Biology from the University of Utrecht (NL) in 2002. After obtaining his PhD from the University of Zurich (CH) in 2006, he joined the Dana Farber Cancer Institute (Harvard Medical School) in Boston (US) as a postdoctoral research fellow. In order to carry out his research, Raymond received a one-year stipend from the Swiss National Science Foundation and a 2,5-year fellowship from the Dutch Cancer Society. The latter fellowship enabled him to come back to the Netherlands in 2009 where he successfully finished his research project at the Hubrecht Institute in Utrecht. In his 7+ years at the bench he used the fruitfly, zebrafish and cell culture systems to elucidate the molecular mechanisms of signaling pathways involved in cancer. He authored 7 papers in renowned international peer reviewed journals. With his strong academic background, Raymond joined SMS-oncology as a Consultant in January 2010. In this position as well as in his role of Contract & Proposal Manager, he has been appreciated for his proficient advice in many oncology drug development projects. Because of Raymond’s excellent ability to translate science into realistic and pragmatic clinical study designs and goals that are driven by sponsors’ needs and expectations, he was promoted to Director Consultancy and supervised the consultancy group from October 2012 to February 2015. As of January 2014, Raymond is CBDO and successfully contributes to the continuous growth of SMS-oncology both through sales as well as through the development and fine tuning of processes and systems.

Edwin Klumper MD PhD MBA
Co-founder & Chief Medical Officer (CMO)

Edwin Klumper  

Edwin carries over 20+ years of experience in Cancer Research and the Pharmaceutical Industry both in Big Pharma as well as small biotech. Trained as an MD, Edwin obtained a PhD in Medicine after devoting 5 years of cancer research on drug resistance and chemosentivity in Leukemia testing panels of 20 drugs on patient samples. He jumpstarted his career as Medical Director for Yew Tree Pharma, a small startup company that developed taxane products and that was later acquired by Bristol Myers Squibb. After serving as local Business Unit Director Oncology for mid-sized Asta Medica, Edwin joined Amgen to successfully build a team to launch Aranesp in The Netherlands, to turn around the Business Unit in the UK, before taking on responsibility for Aranesp Nephrology in Europe as Brand Director at Amgen Headquarters Europe based in Switzerland. With a keen interest in the dynamics of biotech and drug development he Joined Nabi Biopharmaceuticals Europe in Ireland as Vice-President Marketing & Sales to build its commercial operations. After following the executive course ‘Leadership in Biotechnology’ at Harvard Business School in Boston, Edwin decided to combine his business interest with his science and medical background and joined SMS-oncology as co-founder.

René de Keijzer
Chief Financal Officer (CFO)

RenĂ© de Keijzer  

René has more than 30 years’ experience in accounting and finance. He studied public accounting and finance, graduated as a Certified Public Accountant in 1988. Starting his career, Rene gained over 10 years of experience at the Big 4 audit firms KPMG and Arthur Andersen before starting his own accounting and audit firm De Keijzer Nipius in 1992. He brought this firm to 100+ employees before merging it in 2014 with Crowe Horwath Foederer. During these years, he acted on board level for many of his clients. Amongst others, he advised on IPOs, numerous acquisitions and strategic alliances and M&A transactions, national as well as cross-boarder. During his public accounting career, he specialized in start-ups as well as in the biomed/biotech industry. He advised CROs, biotech companies and several medtech companies on strategic and financial level. Many of these companies have grown from startup to medium sized enterprises before taken over by international industry leaders. He also held a Supervisory Board position at a stock-quoted company. René retired from public accounting in 2016 and accepted a position as Chief Financial Officer (CFO) at SMS-oncology. In this position, he supports the management team at strategic and financial level serving SMS-oncology in realizing its business goals for the future.

Contact us for more information Request for proposal